Inaba Kenji, Teixeira Pedro G R, David Jean-Stephane, Chan Linda S, Salim Ali, Brown Carlos, Browder Timothy, Beale Elizabeth, Rhee Peter, Demetriades Demetrios
Division of Trauma Surgery and Surgical Critical Care, Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA.
J Am Coll Surg. 2008 Mar;206(3):432-8. doi: 10.1016/j.jamcollsurg.2007.10.005. Epub 2007 Nov 26.
The purpose of this study was to evaluate the effect of beta-blockers on patients sustaining acute traumatic brain injury. Our hypothesis was that beta-blocker exposure is associated with improved survival.
The trauma registry and the surgical ICU databases of an academic Level I trauma center were used to identify all patients sustaining blunt head injury requiring ICU admission from July 1998 to December 2005. Patients sustaining major associated injuries (Abbreviated Injury Score > or = 4 in any body region other than the head) were excluded. Patient demographics, injury profile, Injury Severity Score, and beta-blocker exposure were abstracted. The primary outcomes measure evaluated was in-hospital mortality.
During the 90-month study period, 1,156 patients with isolated head injury were admitted to the ICU. Of these, 203 (18%) received beta-blockers and 953 (82%) did not. Patients receiving beta-blockers were older (50 +/- 21 years versus 38 +/- 20 years, p < 0.001), had more frequent severe (Abbreviated Injury Score > or = 4) head injury (54% versus 43%, p < 0.01), Glasgow Coma Scale < or = 8 less often (37% versus 47%, p = 0.01), more skull fractures (20% versus 12%, p < 0.01), and underwent craniectomy more frequently (23% versus 4%, p < 0.001). Stepwise logistic regression identified beta-blocker use as an independent protective factor for mortality (adjusted odds ratio: 0.54; 95% CI, 0.33 to 0.91; p = 0.01). On subgroup analysis, elderly patients (55 years or older) with severe head injury (Abbreviated Injury Score > or = 4) had a mortality of 28% on beta-blockers as compared with 60% when they did not receive them (odds ratio: 0.3; 96% CI, 0.1 to 0.6; p = 0.001).
Beta-blockade in patients with traumatic brain injury was independently associated with improved survival. Older patients with severe head injuries demonstrated the largest reduction in mortality with beta-blockade.
本研究旨在评估β受体阻滞剂对急性创伤性脑损伤患者的影响。我们的假设是,使用β受体阻滞剂与提高生存率相关。
利用一所一级学术创伤中心的创伤登记数据库和外科重症监护病房(ICU)数据库,确定1998年7月至2005年12月期间所有因钝性头部损伤而需入住ICU的患者。排除伴有严重相关损伤(头部以外任何身体部位的简明损伤评分≥4分)的患者。提取患者的人口统计学资料、损伤情况、损伤严重程度评分和β受体阻滞剂使用情况。评估的主要结局指标是院内死亡率。
在为期90个月的研究期间,1156例单纯头部损伤患者入住ICU。其中,203例(18%)接受了β受体阻滞剂治疗,953例(82%)未接受。接受β受体阻滞剂治疗的患者年龄较大(50±21岁对38±20岁,p<0.001),重度(简明损伤评分≥4分)头部损伤更常见(54%对43%,p<0.01),格拉斯哥昏迷量表评分≤8分的情况较少见(37%对47%,p = 0.01),颅骨骨折更多(20%对12%,p<0.01),且更频繁地接受颅骨切除术(23%对4%,p<0.001)。逐步逻辑回归分析确定使用β受体阻滞剂是死亡率的独立保护因素(调整后的优势比:0.54;95%可信区间,0.33至0.91;p = 0.01)。亚组分析显示,重度头部损伤(简明损伤评分≥4分)的老年患者(55岁及以上)使用β受体阻滞剂时的死亡率为28%,未使用时为60%(优势比:0.3;96%可信区间,0.1至0.6;p = 0.001)。
创伤性脑损伤患者使用β受体阻滞剂与生存率提高独立相关。重度头部损伤的老年患者使用β受体阻滞剂后死亡率降低幅度最大。